KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Discontinued OperationsCash from Discontinued OperationsCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Free Cash Flow (2016 - 2026)

TherapeuticsMD filings provide 17 years of Free Cash Flow readings, the most recent being $944000.0 for Q1 2026.

  • On a quarterly basis, Free Cash Flow rose 35.05% to $944000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $2.7 million, a 28.65% increase, with the full-year FY2025 number at $2.5 million, up 109.74% from a year prior.
  • Free Cash Flow hit $944000.0 in Q1 2026 for TherapeuticsMD, up from $375000.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $30.2 million in Q4 2022 to a low of -$20.7 million in Q2 2022.
  • Median Free Cash Flow over the past 5 years was $17000.0 (2024), compared with a mean of -$539705.9.
  • Biggest five-year swings in Free Cash Flow: plummeted 134.03% in 2023 and later skyrocketed 2105.88% in 2025.
  • TherapeuticsMD's Free Cash Flow stood at $30.2 million in 2022, then tumbled by 116.4% to -$5.0 million in 2023, then soared by 100.34% to $17000.0 in 2024, then skyrocketed by 2105.88% to $375000.0 in 2025, then soared by 151.73% to $944000.0 in 2026.
  • The last three reported values for Free Cash Flow were $944000.0 (Q1 2026), $375000.0 (Q4 2025), and $999000.0 (Q3 2025) per Business Quant data.